Thermo Fisher Scientific Inc. $TMO Shares Purchased by Davis Rea LTD.

Key Points

• Davis Rea LTD. has increased its position in Thermo Fisher Scientific by 14.8%, acquiring a total of 43,294 shares valued at approximately $17.57 million.
• Wall Street analysts have generally upgraded their outlook on Thermo Fisher Scientific, with a consensus target price of $593.43 and a majority of analysts rating the stock as a "Buy."
• Thermo Fisher Scientific reported an earnings per share (EPS) of $5.36 for the last quarter, exceeding estimates, with a year-over-year revenue growth of 2.9%.

Davis Rea LTD. increased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 14.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 43,294 shares of the medical research company's stock after purchasing an additional 5,582 shares during the period. Thermo Fisher Scientific accounts for approximately 4.4% of Davis Rea LTD.'s portfolio, making the stock its 6th largest position. Davis Rea LTD.'s holdings in Thermo Fisher Scientific were worth $17,573,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. CBIZ Investment Advisory Services LLC increased its stake in Thermo Fisher Scientific by 137.5% in the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock valued at $28,000 after purchasing an additional 33 shares during the last quarter. Anderson Financial Strategies LLC purchased a new position in Thermo Fisher Scientific in the first quarter valued at approximately $30,000. Keystone Global Partners LLC purchased a new position in Thermo Fisher Scientific in the first quarter valued at approximately $31,000. DiNuzzo Private Wealth Inc. increased its stake in Thermo Fisher Scientific by 406.7% in the second quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company's stock valued at $31,000 after purchasing an additional 61 shares during the last quarter. Finally, HighMark Wealth Management LLC increased its stake in Thermo Fisher Scientific by 140.6% in the second quarter. HighMark Wealth Management LLC now owns 77 shares of the medical research company's stock valued at $31,000 after purchasing an additional 45 shares during the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on TMO shares. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Saturday, October 4th. Barclays raised their target price on shares of Thermo Fisher Scientific from $550.00 to $585.00 and gave the stock an "overweight" rating in a research report on Thursday, October 2nd. HSBC restated a "hold" rating and set a $510.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Raymond James Financial restated an "outperform" rating and set a $535.00 target price (up from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Finally, Wells Fargo & Company lowered their target price on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a research report on Thursday, July 24th. Sixteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $593.43.

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $524.95 on Friday. The firm's fifty day moving average price is $488.68 and its 200 day moving average price is $448.39. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $610.97. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The firm has a market cap of $198.23 billion, a price-to-earnings ratio of 30.36, a price-to-earnings-growth ratio of 2.90 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping the consensus estimate of $5.22 by $0.14. The company had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business's revenue was up 2.9% on a year-over-year basis. During the same period in the previous year, the firm earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 400 shares of the business's stock in a transaction on Friday, September 5th. The shares were sold at an average price of $500.50, for a total transaction of $200,200.00. Following the sale, the chief executive officer directly owned 113,762 shares in the company, valued at approximately $56,937,881. The trade was a 0.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the business's stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president owned 22,367 shares in the company, valued at $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 30,066 shares of company stock worth $14,182,963. Corporate insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.